       Document 0275
 DOCN  M9440275
 TI    Decreased reactivity to PPD among HTLV-I carriers in relation to virus
       and hematologic status.
 DT    9404
 AU    Welles SL; Tachibana N; Okayama A; Shioiri S; Ishihara S; Murai K;
       Mueller NE; Department of Epidemiology, Harvard School of Public
       Health,; Boston, MA.
 SO    Int J Cancer. 1994 Feb 1;56(3):337-40. Unique Identifier : AIDSLINE
       MED/94148536
 AB    Data on human T-cell lymphotropic-virus-type-I (HTLV-I) status and
       hematology from 528 individuals were analyzed for associations with low
       reactivity to the purified protein derivative (PPD) of Mycobacterium
       tuberculosis recall antigen. Subjects were classified as HTLV-I carriers
       with abnormal lymphocytes (Ably), carriers without Ably, and
       seronegatives. All carriers had a significant 2.6-fold risk of being low
       responders to PPD compared with the seronegatives, carriers with Ably
       having the highest relative risk. Carriers with HTLV-I-antibody titer >
       or = 1:256, or with other detectable markers of virus status such as
       antibody to tax and proviral DNA, had increased risk for low response to
       PPD similar to the estimate for HTLV-I seropositivity alone, compared
       with the seronegatives. Subjects with a low lymphocyte count had 3.5
       times the risk for being low responders to PPD, compared with subjects
       with high counts. Similarly, subjects with a low monocyte count had 2.0
       times the risk for low reactivity of those with a moderate to high
       count. Results were not confounded by age, sex, smoking or alcohol
       drinking. Using multiple logistic regression, only HTLV-I seropositivity
       and low lymphocyte and monocyte counts were predictive of low reactivity
       to PPD. Analysis indicates that suppression of delayed-type
       hypersensitivity is associated with HTLV-I infection per se, and not
       with viral replication or load. Furthermore, this effect may occur in
       part via changes in the number and function of lymphocytes and
       monocytes. Such a mechanism may involve altered cytokine production in
       carriers and concomitant changes in cell populations involved in
       delayed-type hypersensitivity.
 DE    Carrier State/*BLOOD/*IMMUNOLOGY  Female  Human  HTLV-I Antibodies/BLOOD
       HTLV-I Infections/*BLOOD/*IMMUNOLOGY  *Leukocyte Count
       Lymphocytes/IMMUNOLOGY  Male  Middle Age  Mycobacterium
       tuberculosis/*IMMUNOLOGY  Reference Values  Regression Analysis
       Support, Non-U.S. Gov't  Support, U.S. Gov't, P.H.S.  *Tuberculin Test
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

